Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

CAN THE BEST OF VACCINES DO THIS??? Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19, says the company. VIP is known to target the VPAC1 receptor of the alveolar type II cell (ATII) cell and protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. In addition, VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies. https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-covid-19-therapeutic